Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Buy” from Analysts

by · The Markets Daily

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $66.75.

Several equities research analysts have recently commented on ARCT shares. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, December 17th.

Get Our Latest Stock Analysis on ARCT

Arcturus Therapeutics Stock Up 2.4 %

Shares of NASDAQ ARCT opened at $16.97 on Wednesday. The firm has a market cap of $459.67 million, a PE ratio of -7.64 and a beta of 2.62. The company’s fifty day simple moving average is $17.68 and its 200 day simple moving average is $20.51. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. During the same period last year, the business posted ($0.61) EPS. On average, equities analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current year.

Insider Activity at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This trade represents a 2.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in Arcturus Therapeutics during the third quarter worth $42,000. Quest Partners LLC raised its stake in shares of Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Arcturus Therapeutics during the second quarter valued at about $142,000. Finally, Point72 DIFC Ltd purchased a new stake in Arcturus Therapeutics during the second quarter worth about $188,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

(Get Free Report

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Featured Stories